CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today...
Doubles down on its commitment to connecting the world with the right doctors and advancing healthcare innovation and inclusionNEW YORK,...
– IND for QTX3544 is third for Quanta within one year – – Initiated combination portion of Phase 1 clinical...
Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment...
- Achieved 100% revenue growth versus prior year – - Received Investigational Device Exemption approval from the FDA for the...
Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicineWill provide key regulatory...
- Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009:...
Araris will use proprietary AraLinQ™ linker-conjugation platform to generate novel ADCs using antibodies against targets provided by ChugaiAraris to receive...
Continued Strong Clinical Progress and Planned New Combination Trial Provide Significant Momentum for 2025NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE)...
WALTHAM, Mass. and BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on...
NORWOOD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced...
Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract...
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field...
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the...
BETHESDA, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...
WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...
Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/...
CHICAGO, Jan. 7, 2025 /PRNewswire/ -- International law firm McDermott Will & Emery has appointed Kristian (Krist) Werling to be the new global...
Agreement aims to enhance Pillar's PiVAT® bioinformatics platform with downstream reporting capabilities. NATICK, Mass., Jan. 7, 2025 /PRNewswire/ -- Pillar...
New claims-sourced RADAR models demonstrate positive predictive value BOSTON, Jan. 7, 2025 /PRNewswire/ -- Together Senior Health (Together), a Linus Health...